Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$71.55 USD
+0.48 (0.68%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $71.43 -0.12 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AXSM 71.55 +0.48(0.68%)
Will AXSM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
Other News for AXSM
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Axsome Therapeutics (AXSM) and SAGE Therapeutics (SAGE)
Mizuho dismisses Axsome short report after management call
What You Missed On Wall Street This Morning
Culper Research short Axsome Therapeutics, sees shares 'headed lower'
Culper Research says short Axsome Therapeutics